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ABSTRACT
EZH2 is a negative prognostic factor and is overexpressed or activated in most
human cancers including head and neck squamous cell carcinoma (HNSCC). Analysis
of The Cancer Genome Atlas (TCGA) HNSCC data indicated that EZH2 over-expression
was associated with high tumor grade and conferred poor prognosis. EZH2 inhibition
triggered cell apoptosis, cell cycle arrest and decreased cell growth in vitro. MICU1
(mitochondrial calcium uptake1) was shown to be down regulated when EZH2
expression was inhibited in HNSCC. When the EZH2 and MICU1 were inhibited, HNSCC
cells became susceptible to cell cycle arrest and apoptosis. Mitochondrial membrane
potential and cytosolic Ca2+ concentration analysis suggested that EZH2 and MICU1
were required to maintain mitochondrial membrane potential stability. A xenograft
tumor model was used to confirm that EZH2 depletion inhibited HNSCC cell growth
and induced tumor cell apoptosis. In summary, EZH2 is a potential anti-tumor target
in HNSCC.

INTRODUCTION

molecular mechanism and find a more affective molecular
target with diagnosis and therapeutic potential in HNSCC.
Enhancer of zeste homolog 2 (EZH2), a catalytic
component of Polycomb repressive complex 2 (PRC2),
involved in the regulation of homeotic(Hox) gene
expression and in the early steps of X-chromosome
inactivation [5, 6]. Mounting evidence demonstrated that

Head and neck squamous cell carcinoma (HNSCC)
is the six common cancers of human beings [1]. Although
a systemic treatment strategy is practiced in treating the
patients with HNSCC, the overall survival remains low
[2-4]. There is an urgent need to better understand the
www.impactjournals.com/oncotarget
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Table 1: Correlation between EZH2 and clinical-pathologic characteristics of patients with HNSCC

EZH2 function as an oncogene and a negative prognosis
factor involving in carcinogenesis in many human cancer
types [7-11]. EZH2 contains a SET domain with histone
methyltransferases activity, which catalyses trimethylation
of lysine 27 in histone 3 (H3K27me3) [12]. EZH2 and
the other three core accessory proteins (EED, SUZ12,
and RbAp46/48) induce chromatin compaction and
consequently prevent transcription of target genes [12, 13].
In most cancer types, elevated EZH2 function
has predominantly been associated with tumor cell
proliferation, cell cycle and migration [14-17]. EZH2
mediated tumor suppressor genes’ silencing contributes to
cancer progression. P21, p16 and NLK are validated to be
direct targets of EZH2 [14, 18]. In human HNSCC cells,
loss of EZH2 partially interfered with proliferation and
invasion ability in vitro and in vivo. However, whether and
how targets EZH2 inducing cell apoptosis is still missing.
Apoptosis is a cellular procedure that is regulated
by different regulatory molecules and the dysfunction
of apoptosis results in various pathological disorders in
humans such as cancers [19]. Escape from apoptosis is a
key attribute of tumor cells and facilitates proliferation.
The mitochondrial dependent cell death pathway
integrates stress and survival signaling to govern whether
a cancer cell will live or die [20]. It is characterized by
the loss of mitochondrial membrane potential(ΔΨm)
www.impactjournals.com/oncotarget

[21]. Mitochondrial calcium uniporter (MCU), a
notable mitochondrial Ca2+ uniporter complex, has
been demonstrated to be regulated through its subunit
mitochondrial calcium uptake 1(MICU1) in human models
[22-24].
In the present work, we first analyzed EZH2
expression in a Chinese HNSCC cohort and HNSCC
cohort form TCGA, and we further identify inhibition
of EZH2 inducing HNSCC cell apoptosis in cell lines in
vitro and in a Cal27 derived tumor model. We determined
that mitochondrial dependent apoptosis in HNSCC cell
was significantly induced when EZH2 was depleted and
targeting EZH2 might represent a powerful strategy for the
development of novel therapies interfering with distinct
aspects of HNSCC.

RESULTS
EZH2 was highly expressed in HNSCC and
conferred to poor patient survival
First, we analyzed EZH2 expression in a Chinese
HNSCC cohort of 97 cases and normal oral cavity
mucosa samples of 16 cases by using IHC assay. 12 of
33721
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16 normal oral cavity mucosa samples showed negative
staining of EZH2. In agree with previous studies, human
HNSCC displayed positive expression of EZH2 in tumor
cell nuclei (Figure 1A). There were 49 HNSCC samples
showed positive expression of EZH2 and 48 negative
(50.51%). No statistical significance of EZH2 expression
was determined between groups with different age at
diagnosis and sex status (Table1). HNSCC with larger
tumor size ( > 2cm) showed a higher positive rate of EZH2
comparing with the smaller tumor size group (≤2cm, χ2 =
7.980, P = 0.006). Similarly, EZH2 expression of TNM
stage IV HNSCC was higher than that of TNM stage I-III
tumors (χ2 = 8.743, P = 0.037). Apart from tumor size and
clinical stage, EZH2 was differently expressed among the

HNSCC samples with different histological types. EZH2
expression was lower in well or moderate differentiated
HNSCC than in poorly differentiated tumors (χ2 = 11.587,
P = 0.003) (Table 1). These data implied EZH2 is a
potential marker with diagnosis potential in HNSCC.
Second, to further study the signiﬁcance of high
EZH2 expression for prognosis in HNSCC patients, we
established four EZH2 status patient groups by using
quantile based on RNAseq form The Cancer Genome
Atlas (TCGA). Kaplan-Meier survival analysis showed
that the patients with upper quantile EZH2 expression
showed shorter survival comparing with the rest patients
(P < 0.05; Figure1B). EZH2 expression of different tumor
grades displayed obvious difference (P < 0.05; Figure 1C).

Figure 1: EZH2 was highly expressed in HNSCC and conferred to poor patient survival. A. Representative images of
immunohistochemical staining of EZH2 from human HNSCC. B. TCGA data analysis indicated that upper quantile EZH2 expression
showed shorter survival comparing with the rest patients (P < 0.05). C. EZH2 expression of different tumor grades displayed obvious
difference, y axis showed the log10 RPKM of EZH2 in TCGA datasets.
www.impactjournals.com/oncotarget
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Targeting EZH2 suppressed its function in
HNSCC cells

EZH2 was required for growth of HNSCC in vitro
Since our previous report indicated that EZH2
inhibition suppressed glioma cell growth by regulating
cell cycle progression, we hypothesized that there was a
similar phenomenon in HNSCC. We employed several in
vitro assays to demonstrate the requirement of EZH2 for
HNSCC growth.
MTT assay indicated that, DZNep treated Cal27 and
SCC25 cell showed significantly reduction of cell viability
comparing with DMSO treated cells at 24h, 48h and
72h (P < 0.05, Figure 3A, 3B), and the most significant
reduction of cell viability is 48h after DZNep treatment.
Flow-cytometry data revealed that significant G1 phase
increase was observed in EZH2 treated Cal27 (1.161.34 folds) and SCC25 (1.18-1.39 folds) cells (P < 0.05,
Figure 3C, 3D). Clone formation assay indicated that, 15
days after a single does-treatment of DZNep, the clones
density of Cal27 reduced from (14.8 ± 2.6) to (5.3 ± 2.6)
(per 100mm2) (P < 0.05), and the clones density of SCC25
reduced from (14.5 ± 4.2) to (4.5 ± 1.3) (per 100mm2) (P

Cal27 and SCC25 cells showed higher expression
of EZH2, H3K27me3 and MICU1 comparing with
Tb3.1, UM1 and Hep-2 cell lines (Figure 2A). To address
EZH2’s role in HNSCC, we blocked EZH2 activity in
human HNSCC by chemical inhibition using DZNep.
Cell viability curve indicated that, comparing with Cal27
cell (IC50 = 6μM), SCC25 (IC50 = 3μM) was more
sensitive to DZNep (Figure 2B). DZNep treatment led to
considerable reduction of EZH2, H3K27me3 and MICU1
expression in a dose-dependent manner (Figure 2C).
Moreover, we employed EZH2 siRNA (si-EZH2) to block
EZH2, the results showed that the expression of EZH2 and
MICU1 were decreased (Figure S2A).

Figure 2: DZNep suppressed EZH2 function in HNSCC cell. A. EZH2, MICU1 and H3K27me3 expression were determined by

western blot analysis in five HNSCC cell lines. B. The cell viability curve of Cal27 and SCC25 cell lines. C. Western blot analysis of Cal27
and SCC25 cells shows the expression of EZH2, MICU1 and H3K27me3 after treatment with DZNep at 48 h, with GAPDH and Histone
3 serving as loading control.
www.impactjournals.com/oncotarget
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the anti-apoptosis role of DZNep or si-EZH2 in treating
HNSCC. DZNEP induced early and latent phase of
apoptosis in Cal27 (DMSO: 0.6%, DZNep (2μM: 9.5%,
6μM: 20.2%), P < 0.05) and SCC25 (DMSO: 0.3%,
DZNep (1μM: 5.6%, 3μM: 15.4%), P < 0.05, Figure
4A) cell line, and si-EZH2 also induced early and latent
phase of apoptosis in two cell lines. To assess the effect of
EZH2 inhibition in inducing cell senescence, senescencerelated β-galactosidase staining is employed. In contrast
to DMSO treated cells, DZNep treated Cal27 and SCC25
cells displayed a 9- to 10-fold (P < 0.05) higher SA-β-Gal

< 0.05, Figure3E, 3F). The cell cycle dependent oncogene
Cyclin D1 level was down-regulated while p16 and p21
expression were up-regulated by EZH2 blockage (Figure
3G).

Targeting EZH2 induced apoptosis of HNSCC in
vitro
Anti-apoptosis is the common feature of cancer
progression. We employed Annexin V/PI assay to evaluate

Figure 3: EZH2 was required for growth of HNSCC in vitro. A., B. Cal27 and SCC25 cells proliferation were significantly
impaired after DZNep treatment for 48h as measured by MTT assay (* represent P < 0.05). C., D. Flow-cytometry was performed to
examine the G1/S arrest effect in Cal27 and SCC25 cells after treatment with DZNep at 48h (P < 0.05). E., F. Reduction of clone formation
ability in DZNep- treated Cal27 (6 μmol/L) and SCC25 (3μmol/L) cells (P < 0.05). G. Western blot analysis shows the expression of Cyclin
D1, p16, p21 in both cells treated with DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L) at 48h, with GAPDH as a loading control (P < 0.05).
www.impactjournals.com/oncotarget
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the cyto-Ca2+regulator MICU1 expression in both cell
lines. MCU expression showed no significant changes by
DZNep treatment. By contrast, Cytochrome c expression
was increased dramatically (Figure 5C).
Thirdly, we investigated the correlations between
EZH2 and other apoptosis related genes by using linear
regression association test in HNSCC dataset published by
TCGA. A gene with p-value less than 0.05 was considered
to be significantly EZH2-associated. We observed that
EZH2 was positively associated with CBARA1 (MICU1),
BCL2 and MKI67, and negatively associated with CASP4,
CCND1 and CDKN1A in the term of expression (P < 0.05,
see Figure S1A-F).

activity in both cell cultures (Figure 4B, 4C). Similarly, siEZH2 increased SA-β-Gal activity in two cell lines (Figure
S2D, E). We then analyzed the changes in the levels of
pro-apoptotic proteins BAX, and Cleaved caspase-3, and
anti-apoptotic protein Bcl-2. The results indicated that
Bcl-2 was decreased and BAX or Cleaved caspase-3 was
increased by DZNep or si-EZH2 treatment in both cell
lines (Figure 4D, S2F).
Moreover, the loss of ΔΨm is an early event in
apoptosis. ΔΨm was detected by JC-1 fluorescent probe.
As shown in Figure 5A, when Cal27 and SCC25 cell were
treated with DZNep for 24h, ΔΨm was drastically reduced
respectively in both cell lines. We measured ΔΨm after
Cal27 and SCC25 cell were transfected with si-EZH2, the
result showed that si-EZH2 reduced ΔΨm in both cell lines
(Figure S2C). Next we used Ca2+ indicator, Fluo 3-AM, to
determine the free Ca2+ level induced by EZH2 inhibition.
The results showed that DZNep treatment of Cal27 and
SCC25 cell increased Ca2+ accumulation in cytoplasm
(Figure 5B). More importantly, DZNep treatment inhibited

MICU1 regulated HNSCC cell apoptosis in vitro
Next, we employed a MICU1 shRNA (shMICU1)
vector to further validate the role of targeting EZH2/
MICU1 in regulating cell apoptosis in HNSCC cells. We
first analyzed the MICU1 expression changes induced by

Figure 4: Targeting EZH2 induced apoptosis of HNSCC in vitro. A. The percentages of apoptotic cells were significantly
increased by DZNep treatment in a dose dependent (P < 0.05). B., C. SA-β-gal staining positive cells were determined and compared after
Cal27 and SCC25 cells were treated with DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L) or DMSO for 48h (P < 0.05). D. Western blot
analysis shows the expression of BAX, Bcl-2, Cleaved caspase-3 in both cells treated with DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L)
at 48h, with GAPDH as a loading control (P < 0.05).
www.impactjournals.com/oncotarget
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shMICU1 in both cell lines, and shMICU1-3 treatment
showed the robust effect in inhibiting MICU1 expression
(Figure 6A). Thus, we selected shMICU1-3 for further
research usage. The Annexin V/PI assay results indicated
a significant increase in cell apoptosis with the depletion
of MICU1, the ratio of early apoptotic cell increased
from 0.28% to 8.75% in Cal27 and 0.18% to 4.66% in
SCC25 (P < 0.05, Figure 6B). Moreover, we combined
MICU1 expression vector (GV230-MICU1) with DZNEP
treated two cell lines, the ratio of early apoptotic cell is
4.7% in Cal27 and 2.26% in SCC25 (P < 0.05, Figure
6B). As shown in Figure 6C, when Cal27 and SCC25 cell
were treated with shMICU1 for 48h, ΔΨm was drastically
reduced respectively in both cell lines and Ca2+ indicator
suggested free Ca2+ level induced by MICU1 targeting
(Figure 6C, 6D). Western blot analysis showed that Bcl2 was decreased and BAX or Cleaved caspase-3 was
increased by shMICU1 treatment in both cell lines (Figure

6E). Moreover, we introduced GV230-MICU1 into Hep-2
cell that had a low endogenous MICU1 expression level as
shown in Figure 2A. Early apoptosis rate decreased from
3.6% to 0.8% in Hep-2 (Figure 6F). Western blot analysis
showed that anti-apoptotic protein MICU1 and Bcl-2
was increased (Figure 6G). These data provide important
evidence that MICU1 play an important role in EZH2regulated cell death pathway.

Targeting EZH2 inhibited HNSCC tumor growth
and induced apoptosis in vivo
To better illustrate the role of EZH2 in HNSCC
tumor growth, we established HNSCC xenograft tumor
model using Cal27 cell lines. Comparing with DMSO
treated tumors, DZNep treated tumors showed significant
reduction of tumor volume and weight (P < 0.05, Figure

Figure 5: Targeting EZH2 affected mitochondrial membrane potential balance. A. Mitochondrial membrane potentials
were reduced by DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L), the evident in confocal image soft the fluorescent dye JC-1 in Cal27
and SCC25 cell lines. B. Ca2+ indicator to determine the free Ca2+ level induced by DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L). C.
Western blot analysis shows the expression of Cytochrome c, MICU1, MCU in both cells treated with DZNep (Cal27: 6μmol/L and SCC25:
3μmol/L) at 48h, with GAPDH as a loading control (P < 0.05).
www.impactjournals.com/oncotarget
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DISCUSSION

7A-7C). TUNEL assay was used to determine the DNA
fragmentation, which was the hallmark of apoptotic cells.
The results indicated that DZNep treatment induced more
apoptotic nuclei than in DMSO treated Cal27 xenograft
tumors (Figure 7D). Strikingly, HE staining showed
morphological changes in Cal27 tumors by DZNep
treatment. For example, in DZNep treated group, Cal27
tumors displayed less mitotic figures, chromosome
staining and cell density (Figure 7E). Most importantly,
comparable to controlled tumors, DZNep treatment was
sufficient to attenuate cell proliferation protein Ki-67,
cyto-Ca2+ regulator MICU1, anti-apoptotic protein Bcl2 as well as EZH2, and to increase Cleaved caspase-3
expression in vivo (Figure 7E).

In this study, we demonstrate over-expressed EZH2
to be a key target with diagnosis and therapeutic potential
in HNSCC. Analysis of HNSCC TCGA dataset suggested
EZH2 activity might influence the downstream apoptosis
related genes. Importantly, inhibition of EZH2 with
chemical synthesized compound DZNep, induced loss
of ΔΨm and cell apoptosis in HNSCC cell in vitro and
in vivo. We also reported that EZH2 inhibition induced
MICU1 inactivation and cyto-Ca2+ accumulation which
might be the underling mechanism.
Elevated EZH2 levels often are directly correlated
with advanced metastatic stages of cancer progression
and poor prognosis. In glioma and renal cell carcinomas,
increased EZH2 expression was associated with tumor
grade and high expression of EZH2 was determined to be a

Figure 6: MICU1 regulated HNSCC cell apoptosis in vitro. A. MICU1 expression changes induced by shMICU1 in both cell

lines. B.: Flow cytometry was performed to examine the apoptosis of Cal27 and SCC25 cells after transfection with ShMICU1 or GV230MICU1 combining with DZNep (Cal27: 6μmol/L and SCC25: 3μmol/L). C. Ca2+ indicator to determine the free Ca2+ level induced by
MICU1 inhibition. D. Mitochondrial membrane potentials were reduced by MICU1 inhibition, the evident in confocal image soft the
fluorescent dye JC-1 in Cal27 and SCC25 cell lines. E. Western blot analysis shows the expression of BAX, Bcl-2, Cleaved caspase-3 in
both cells treated with ShMICU1 at 48h, with GAPDH as a loading control (P < 0.05). F. Flow-cytometry was performed to examine the
apoptosis of Hep-2 after transfection with GV230-MICU1. G. Western blot analysis shows the expression of MICU1, Bcl-2 in Hep-2 cell
treated with GV230-MICU1 at 48h, with GAPDH as a loading control (P < 0.05).
www.impactjournals.com/oncotarget
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strong and independent predictor of short overall survival
[16, 25]. Comparing with normal mucosa or adjacent
normal tissue, EZH2 was overexpressed in 50-60% of
HNSCC tissues and contributed to tumor differentiation
status [26, 27]. Additionally, EZH2 has been found to
initiate oral leukoplakia malignant transformation and
epithelial-mesenchymal transition in HNSCC [28]. In
the present work, we analyzed the EZH2 expression in
TCGA dataset, and we found the higher expression of
EZH2 might predict shorter overall survival of HNSCC
patients. And examination of HNSCC specimens showed
EZH2 expression was associated with tumor size,
histological differentiation and clinical stage. Our data

further confirmed EZH2 was a robust prognostic factor for
human HNSCC and a biomarker for identifying HNSCC
molecular subtypes.
EZH2 is required for tumor progression in
H3K27me3 dependent manner, and this can be blocked
by EZH2 inhibitors, like GSK126 or EPZ-6438 [29].
In tongue cancer and glioblastoma, EZH2 depletion
suppressed tumor growth by arresting cell cycle
progression [17, 30]. Our data suggested that, we used
pharmacological EZH2 inhibition via DZNep, which
causes proteosomal degradation of EZH2 [31, 32]. DZNep
treatment effectively reduced EZH2 and H3K27me3
expression in both cell lines. Of note, EZH2 inhibition

Figure 7: Targeting EZH2 inhibited HNSCC tumor growth and induced apoptosis in vivo. A.-C. Tumor volume and

weight of DMSO or DZNep-treated animals was measured. D. TUNEL assay showed an induced apoptotic nucleus (green) in DZNeptreated Cal27 tumors (magnification: x1000). E.: Representative images of immunohistochemical staining of EZH2, MICU1, MCU, Ki67,
CyclinD1, Bcl-2, BAX and Cleaved caspase-3 in tissue from mice with tumors derived from Cal27 cells treated with DMSO or DZNep,
and HE staining was used to examine morphological changes (magnification: 200x).
www.impactjournals.com/oncotarget
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impairs tumor cell proliferation ability, cell cycle
progression and anti-apoptisis potential in both cell lines
and this suppressed Cal27 derived tumors’ growth in a
xenograft model. These data fully illustrated that EZH2
serves as a target with therapeutic potential in HNSCC.
To address the mechanism through which EZH2
inhibition effecting tumor cell apoptosis, we found that
HNSCC cell showed spatially increase of cyto-Ca2+ and
loss of ΔΨm was induced by DZNep treatment. A wellestablished notion that MCU is a highly selective channel
with Ca2+ transmission capability and MICU1 has been
shown to regulate the mitochondrial Ca2+uniporter, which
pumps cytosolic Ca2+ into the mitochondria [33]. In the
absence of MICU1, mitochondria become constitutively
loaded with Ca2+, triggering excessive reactive oxygen
species generation and sensitivity to apoptotic stress [23,
34]. Although the underlying mechanisms by which EZH2
regulates MICU1 to prevent HNSCC cell apoptosis is not
entirely clear, our data showed inhibiting EZH2 triggers
cyto-Ca2+ accumulation, loss of ΔΨm, G1 phase cell cycle
arrest and changes on proteins of mitochondrial related
cell death pathway. More importantly, gain or loss function
assays suggested that targeting MICU1 could compensate
EZH2’s effect on regulating tumor cell apoptosis.
On the basis of increasing integrated research and
experimental evidence, it is now fully elucidated that
EZH2 plays a central role in cancer transformation, and
its overexpression is associated with tumor cell antiapoptosis, invasiveness, chemo-resistance in human
cancers including HNSCC. Further, pharmacological
inhibition of EZH2 by using DZNep, GSK503 [35],
GSK126 [36] and etc provided a novel approach in
treating human epithelium cancers. Accordingly, our study
reveals that targeting EZH2 might be a promising strategy
for future therapies of human HNSCC patients.

sections, according to the manufacturer’s instructions.
Each stained slide was jointly scored by 2 pathologists
blinded to the clinical information. For statistical
analysis, positive expression of EZH2 was defined as >
10% of positive-stained cells in the tumor. Two blinded
pathologists independently evaluated the slides. In case of
a discrepancy, the 2 observers simultaneously reviewed
the slides to achieve a consensus.

HNSCC mRNA datasets and analysis
Transcriptom expression datasets and the
corresponding clinical information were downloaded
from websites of The Cancer Genome Atlas (http://
cancergenome.nih.gov).Total 508samples were available
for this analysis. RPKM were calculated from RNA-seq
read counts of each mRNA and log transformations were
performed to increase the normality. We applied linear
regression study the gene co-expression and ordinal data
analysis to study the association between EZH2 expression
and tumor stage information. With survival duration data
from TCGA, we estimated Kaplan-Meier survival curves
of low-risk and high risk groups separated by the mean of
EZH2 expression. Also the Log-rank test were performed
to test the significance of difference of survival curves
between these two groups. Data manipulation, statistical
analysis and visualization were accomplished using R
3.0.2.

Cell lines and culture conditions
Human HNSCC cell line Hep-2 was purchased from
the Institute of Basic Medical Sciences, Chinese Academy
of Medical Sciences. Tb3.1 cell line was a gift from the
Ninth People’s Hospital Shanghai Jiao Tong University.
Cal27, SCC25, UM1 cell lines were was kindly provided
by Prof. JinsongHou of Guanghua School of Stomatology,
Hospital of Stomatology, SunYat-sen University. The cell
lines were maintained in MEM, DMEM or RPMI-1640
(Thermo Scientiﬁc) supplemented with 10% fetal bovine
serum (FBS, Thermo Scientiﬁc) with 5% CO2 at 37℃.

MATERIALS AND METHODS
HNSCC samples and Immunohistochemistry for
EZH2
A total of 97 HNSCC tumor samples from radical
resection were randomly collected at Tianjin Medical
University Cancer Institute & Hospital during January
2009 to December 2012. The demographic and clinical
data was collected from electric records. All the tissue
samples were used for EZH2 expression examination. All
samples were collected with informed consent according
to the Human Tissue Sample Usage Guidelines of the
Tianjin Medical University Medical Ethnic Committee.
Immunohistochemistry staining for EZH2 (Cell
Signaling Technology) of 97 HNSCC samples from Tianjin
Medical University Cancer Institute & Hospital was
performed on formalin-fixed, paraffin-embedded tissue
www.impactjournals.com/oncotarget

Drug treatments
For EZH2 inhibition, Cal27 and SCC25 cells were
treated with 3-Deazaneplanocin A (DZNep) (2 or 6μmol/L
for Cal27 cell, 1or 3μmol/L for SCC25 cell) (Merck
Millipore) dissolved in dimethyl sulfoxide (DMSO,
Sigma-Aldrich) for 48 hours.

SiRNA, ShRNA and vector transfection
SiRNA (GeneChem) was used to knockdown
EZH2 expression in Cal27 and SCC25 cell lines, using
33729
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Lipofectamine 3000 reagent as the manufacturer’s
instructions (Life Technology). The final concentration of
EZH2 siRNA is 75nM. 48h after transfection the Cal27
and SCC25 cell lines were harvest for research usage.
ShRNA (GeneChem) were used to knockdown
MICU1 expression in Cal27 and SCC25 cell lines. 5μg
shRNA was transfected to cells, using Lipofectamine
3000 reagent as the manufacturer’s instructions (Life
Technology).
5μg MICU1 full-length expression vector
(GV230-MICU1, GeneChem) was transfected to 2×106
HNSCC cells by using Lipofectamine3000 reagent as
the manufacturer’s instructions (Life Technology). The
GV230 empty vector (GV230-NC, GeneChem) was used
as the control plasmid. 48h after transfection, the cells
were collected for apoptosis examination and whole cell
lysate were collected for Western blot analysis.

of dual emissions from mitochondrial JC-1 monomers
or aggregates using FV-1000 laser scanning confocal
biological microscopes (Olympus) under Argon-ion
488 nm and 546 nm laser excitation. Mitochondrial
depolarization is indicated by an increase in the green/red
fluorescence intensity ratio.
Ca2+ indicator Fluo-3/AM was used to detect the
intracellular Ca2+. After 24 h, the treated cells and the
control cells, rinsed twice with PBS, were loaded with
theFluo-3/AM (5μM) and continuously cultured at 37℃
for 60 min, at 5% CO2 incubator. The labeled cells were
washed with PBS to remove the unloaded Fluo-3/AM.
After cells were loaded with the fluorescence probe,
changes in intracellular Ca2+of individual cells were
measured using a digital imaging system equipped with
a laser confocal scanning microscope (Olympus) with an
excitation wavelength of 488 nm.
Western blot analysis was employed to assay
protein expression. Total protein is extracted from
DZNEP/shMICU1 treated HNSCC cells. The protein
samples were resolved by SDS-PAGE and transferred
onto PVDF membranes (Roche). The membranes were
then incubated with the following antibodies: EZH2,
MICU1, p16, p21, CyclinD1 and Cleaved caspase-3
(Cell Signaling Technology), MCU and Cytochrome c
(Abcam), Bcl-2 and BAX (Zhongshan Biotechnology),
H3K27me3 (Signalway Antibody). GAPDH (Zhongshan
Biotechnology) or Histone 3 (Cell Signaling Technology)
was used as an internal control.

Cell experiments in vitro
For apoptosis analysis by flow cytometry,
DMSO or DZNep treated Cal27 and SCC25 cells were
digested with trypsin (Gibico) and resuspended as
single-cell suspension. Double staining with fluorescein
isothiocyanate (FITC)-Annexin V and propidium iodide
(PI) was completed using a FITC Annexin V Apoptosis
Detection Kit (Keygen) according to the instructions
provided by the manufacturer. Apoptosis was measured
using flow cytometry.
For cell cycle distribution analysis by flow
cytometry, after DMSO or DZNep treated Cal27 and
SCC25 cells, the cells were trypsinized, fixed in 70%
ethanol, washed once with PBS, and then labeled with
propidium iodide (Keygen) in the presence of RNase
A (Sigma-Aldrich) for 30 min in the dark. Cell cycle
distribution was measured using flow cytometry.
For colony forming assay, 1,000 cells treated with
DZNep or DMSO were seeded into 6-well plates and
allowed to grow for 14 days. The cells were then fixed
and stained with crystal violet. The colonies were further
visualized under an invert microscope and photographed.
Colonies numbers were counted from five different fields
per 100mm2.
SA-β-gal staining (Beyotime Biotechnology) was
performed following the supplier’s instructions. SA-β-gal
positive cells were stained in blue. Total 500 cells from
five different vision fields per section were counted under
a pathology light microscope (Olympus) at 200×. All of
the stained sections were examined by two independent
observers.
JC-1 probe (Beyotime Biotechnology) was
employed to measure mitochondrial depolarization.
Briefly, Cells cultured in confocal capsule after indicated
treatments were incubated with JC-1 staining solution
at 37℃ for 20 min and rinsed twice with PBS. MMP
were monitored by determining the relative amounts
www.impactjournals.com/oncotarget

Cal27 tumor model study
Animal experiments were carried out using BALB/
c-A nude mice at 4 weeks of age, which were purchased
from Vital River Laboratories China. All experimental
animals were injected subcutaneously on the right groin
region with 2×10 6 Cal27 cells. Twenty days later, tumors
were formed, these mice were separated into two groups
(8 mice per group), randomly. The DMSO group, the
DZNep group (0.07 mg/kg dissolved in DMSO) [10].The
mice received an injection into the tumor every three days,
and the size of tumor and mice weights were measured
by calipers and electronic weighing meter. Tumor volume
was calculated as follows: volume = a*b2/2. Tumor
weights were also measured on tumor samples harvested.

TUNEL assay
The cell apoptosis of the tumor samples was
measured by TUNEL assay using an in situ cell death kit
(Roche) by following the manufacture’s protocol. The cell
nucleuses were counterstained by DAPI (Sigma) reagent.
Positive cells were visualized by FV-1000 laser scanning
confocal biological microscopes (Olympus).
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Immunohistochemistry (IHC)
The paraffin-embedded tissue sections were
used for examination of EZH2, MICU1, CyclinD1and
Cleaved caspase-3 (Cell Signaling Technology), MCU
(Abcam), Bcl-2, BAX, Ki-67 (Zhongshan Biotechnology)
expressions. For IHC assay, sections were incubated
with primary antibodies (1:100 dilutions) overnight at
4˚C, followed by a biotin-labeled secondary antibody
(1:100 dilutions) (Zhongshan Biotechnology) for 40 min
at 37 ˚C. Sections were incubated with ABC-peroxidase
anddiaminobenzidine (DAB) (Zhongshan Biotechnology),
counterstained with hematoxylin and visualized using
light microscopy.
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